A 21-year-old woman with severe aplastic anemia underwent allogeneic bone marrow transplantation from an HLA-identical sibling donor. The patient also had chronic hepatitis B and the donor was an HBV carrier. To decrease HBV and improve hepatic dysfunction before BMT, the patient had received lamivudine for 6 months. After marrow transfusion, administration of lamivudine was continued to inhibit replication of donor-derived HBV. The patient showed hematological engraftment on day 13 without any serious liver dysfunction. Eight months after BMT, she is now alive and well without chronic liver GVHD or reactivation of hepatitis B. HBV-DNA was not detected in the patient's serum. Administration of lamivudine to a BMT recipient with chronic hepatitis B may be a safe and promising way to prevent fatal liver dysfunction in the setting of allogeneic BMT, even in the event of BMT from an HBV-positive donor. Bone Marrow Transplantation (2002) 29, 269-271. DOI: 10.1038/sj/bmt/1703350 Keywords: allogeneic bone marrow transplantation; hepatitis B virus; lamivudine Allogeneic BMT has become one of the most effective treatment modalities for patients with hematological diseases. However, myeloablative and immunosuppressive conditioning, acute and chronic GVHD, and administration of immunosuppressive drugs for prophylaxis and treatment of GVHD enhance viral replication with a consequent increase in viral carriers. Reactivation of hepatitis B virus (HBV) infection after allogeneic BMT is well known in carriers.
Allogeneic BMT has become one of the most effective treatment modalities for patients with hematological diseases. However, myeloablative and immunosuppressive conditioning, acute and chronic GVHD, and administration of immunosuppressive drugs for prophylaxis and treatment of GVHD enhance viral replication with a consequent increase in viral carriers. Reactivation of hepatitis B virus (HBV) infection after allogeneic BMT is well known in carriers. 1 Although hepatitis B surface antigen (HBsAg) positivity in the recipient is not generally considered to be a strict contraindication for BMT, patients with chronic HBV infection have a high risk of severe hepatic failure, leading to fulminant hepatitis with a fatal outcome, after transplantation due to reactivation of HBV. 2, 3 Moreover, the use of HBsAg-positive donors, particularly if hepatitis B e antibody (anti-HBe) positive, has been shown to increase the risk of severe liver disease in BMT recipients, and hepatitis B surface antibody (anti-HBs) positivity has been shown to prevent severe liver damage. 4 Recently, lamivudine, which is one of the reverse transcriptase inhibitors of human immunodeficiency virus (HIV) and has been used to treat patients with HIV infection, has been administered to patients with chronic hepatitis B. 5, 6 Several studies have shown the effectiveness of lamivudine for inhibition of HBV reactivation and for clinical and pathological improvement in hepatic dysfunction even in patients with hematological diseases after stem cell transplantation. 7, 8 Here, we report a successful allogeneic BMT from an HBV-positive sibling donor (HBV carrier) into a patient with severe aplastic anemia complicated by chronic hepatitis B, using lamivudine.
Case report
In October 1996, a 21-year-old woman was diagnosed with severe aplastic anemia. She was treated with a combination of cyclosporin A, anti-thymocyte globulin (ATG), and granulocyte colony-stimulating factors, but her pancytopenia did not improve; in fact it worsened, requiring frequent transfusions of RBC and platelets. Since the patient also had chronic hepatitis B (HBsAgϩ, anti-HBsϪ, hepatitis B e antigen: HBeAgϩ, anti-HBeϪ) with a high level of serum HBV-DNA, lamivudine (150 mg/day) was administered to inhibit HBV replication and improve hepatic dysfunction. At 6 months after the start of lamivudine, her serum HBV-DNA and titer of HBeAg had become negative and her serum transaminase levels had improved to within normal ranges. However, her pancytopenia had not improved even after a second course of ATG. She therefore underwent an allogeneic bone marrow transplant from an HLA-matched sibling donor in May 2000. Since the HBV serologic markers of the donor were HBsAgϩ, anti-HBsϩ, HBeAgϩ and anti-HBeϪ and HBV-DNA was 7.5 LGE/ml, we decided to use lamivudine to inhibit replication of HBV not in the donor before BMT but in the recipient after BMT, because of the possibility that stopping the lamivudine might result in reactivation of HBV and induction of hepatitis in the donor. The conditioning regimen was 5 mg/kg of ATG for 5 days, 50 mg/kg of cyclophosphamide for 4
Bone Marrow Transplantation days, and 750 cGy of total lymphoid irradiation. GVHD prophylaxis was with cyclosporin A and short-term methotrexate. Soon after transplantation, the serum HBV-DNA and HBeAg levels increased transiently with a slight worsening of hepatic function (Figure 1 ). However, continuous administration of lamivudine to the host successfully reduced HBV replication, and the HBeAg level gradually decreased thereafter. The patient showed hematological engraftment on day 13 and recovered smoothly thereafter with no evidence of hepatic failure, hepatic GVHD or VOD. She now has hematological recovery without detectable HBV-DNA after the cessation of immunosuppression. The result of a liver biopsy performed on day 100 showed severe hemosiderosis due to frequent blood transfusions, but no signs of GVHD or hepatitis B.
Discussion
Although ongoing or previous HBV infection in donors or recipients is not an absolute contraindication for BMT, the use of HBsAg-positive donors has been reported to increase the risk of severe liver disease in BMT recipients. 4 Therefore, attempts to decrease HBV after BMT are essential to prevent fulminant hepatic failure and VOD. Administration of lamivudine to the donor before the bone marrow harvest may be the easiest way to reduce HBV in harvested marrow; however, there may be a high risk of a rebound increase in HBV after cessation of lamivudine. 8, 9 Since it is still uncertain how long the treatment should be maintained, it is better not to administer lamivudine to an HBVpositive carrier in order to avoid a possible rebound effect. Therefore, in vivo purging with lamivudine in the host after transplantation may be ethically the best way to eradicate HBV. However, if the donor is HBV positive and the patient is HBV negative, it is unethical not to treat the marrow donor. Other scientific and ethical studies are needed to determine the efficacy of this drug as prophylaxis in HBVnegative BMT patients who receive bone marrow from an HBsAg-positive donor.
Although the present patient has had to take lamivudine for a long time to eliminate HBsAg, continuous administration of lamivudine before and after BMT has had no side-effects to date. Restoration of T cell immunity in this patient after BMT may be a risk factor for the development of fulminant hepatitis after cessation of lamivudine. 2 In the present case, the use of lamivudine was effective not only for suppression of HBV and improvement in hepatic dysfunction in the recipient before BMT, but also for suppression of HBV derived from the donor marrow after BMT. However, this observation may only apply to patients with aplastic anemia, and not to much more immunocompromised patients with malignancies. Recent studies have shown the efficacy of lamivudine administered to patients with acute hepatitis B, even when it was started after worsening of chronic hepatitis B.
10 Therefore, not prophylaxis but early initiation of this drug may be sufficient to inhibit HBV replication with careful monitoring of HBV-DNA levels. 11, 12 Since mutation of HBV after administration of lamivudine has been reported, further studies to determine the optimal time of commencing the drug and the optimal duration of drug use is needed. 13 A prospective study on the effectiveness of lamivudine for BMT in HBV-positive patients and donors is warranted.
